Navigation Links
More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
Date:12/3/2008

ion with drugs that have ulcerogenic or hemorrhagic potential, such as non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, oral bisphosphonates or anticoagulants.

The most frequently occurring adverse reactions with a suspected relationship to Exjade were diarrhea, vomiting, nausea, abdominal pain, skin rash and increases in serum creatinine. Maintenance of adequate hydration for patients experiencing diarrhea or vomiting is recommended. Gastrointestinal symptoms, increases in serum creatinine and skin rash were dose related. These commonly reported adverse events were predominantly mild to moderate in severity with serious adverse events reported in 9.1% of patients in the Exjade arm and 8.6% of patients in the deferoxamine arm.

For full prescribing information, please visit www.us.exjade.com.

About Femara

Femara(R) (letrozole tablets) is approved for the adjuvant (following surgery) treatment of postmenopausal women with hormone receptor-positive early stage breast cancer. The benefits of Femara in clinical trials are based on 24 months of treatment. Further follow-up will be needed to determine long-term results, safety and efficacy.

Femara is also approved for the extended adjuvant treatment of early stage breast cancer in postmenopausal women who are within three months of completion of five years of tamoxifen therapy. The benefits of Femara in clinical trial are based on 24 months of treatment. Further follow-up will be needed to determine long-term results, including side effects.

In addition, Femara is approved for the treatment of postmenopausal women with estrogen receptor-positive or estrogen receptor-unknown breast cancer that has spread to another part of the body (metastatic cancer).

You should not take Femara if you are premenopausal. Your doct
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Related medicine technology :

1. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Genta Clinical Programs Featured in Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
4. Biodel Inc. Announces the Completion of Its Two Pivotal Trials and the Release of EASD Abstracts Containing Additional Interim Data From Its VIAject(TM) Program
5. New Data Reveal Topical Divigel(R) (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes
6. Study Results Reveal alli(R) Patient Satisfaction Linked to Weight Loss Achieved; Not Treatment Effects
7. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
8. New Conflict of Interest Violations Revealed at California Stem Cell Institute
9. St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia
10. Protein Tomography(TM) Reveals Molecular Mode of Action of Humax-EGFr Published in PNAS
11. Imaging Results From the ADAGIO-LIPIDS Reveal That Effects of Rimonabant on Cardiometabolic Risk Profile Include Loss of Visceral Fat and Mobilization of Liver Fat
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... Future Prospects for Companies in Antihistamines, Corticosteroids, ... - new study showing you trends, partnerships, and ... allergic rhinitis drugs heading? What are the commercial prospects ... you potential revenues and other trends to 2025, discussing ... report provides 273 tables, charts, and graphs. Discover the ...
(Date:9/4/2015)... , Sep. 04, 2015 ... of the "Investigation Report on China,s Sodium Ibandronate Market, ... and used in the clinic under the trade name of ... Austria in 1996, sodium ibandronate was approved by ... treatment of osteoporosis under the trade name of Boniva. However, ...
(Date:9/4/2015)... September 4, 2015 Hutchison ... that Hutchison MediPharma Limited ("HMP"), its drug R&D ... second proof-of-concept ("POC") trial of fruquintinib in patients ... in China .  The top-line ... meeting the primary efficacy endpoint of progression free ...
Breaking Medicine Technology:Allergic Rhinitis Drugs Market Forecast 2015-2025 2Allergic Rhinitis Drugs Market Forecast 2015-2025 3Allergic Rhinitis Drugs Market Forecast 2015-2025 4Allergic Rhinitis Drugs Market Forecast 2015-2025 5Allergic Rhinitis Drugs Market Forecast 2015-2025 6Allergic Rhinitis Drugs Market Forecast 2015-2025 7Investigation Report on China's Sodium Ibandronate Market 2010-2019 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 3
... Late Stage Clinical Therapeutic Cancer... -- TUEBINGEN, Germany, September 21, 2010 ... ... ... ,; var first_result; // Results are keyed by longUrl, so we need to grab the first one. ...
... Inc., today announced that it reported positive preclinical ... Association for the Study of Diabetes (EASD).  CCX140, ... the chemokine receptor CCR2, improved metabolic function while ... in an animal model, and was well tolerated ...
Cached Medicine Technology:immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 2immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 3immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 4immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 5immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 6immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 7immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 8immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 9immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 10ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD) 2ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD) 3ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD) 4
(Date:9/4/2015)... ... September 04, 2015 , ... The USC Eye Institute ... number 9 nationwide by Doximity. Faculty, residents and staff are honored to have ... in the quality of our ophthalmology residency program. Our faculty places a high priority ...
(Date:9/4/2015)... ... ... access to a doctor can sometimes be a challenge for a variety of reasons. ... affects hospitals’ abilities to provide quality service to those with serious needs, increases insurance ... has recently presented itself, the new telemedicine platform and app, DocChat . ...
(Date:9/4/2015)... ... September 04, 2015 , ... Lalonde Gordon ran a 44.64 seconds scorcher in ... in the men’s 400 meters final, with an impressive 44.89 seconds at the 2015 ... Jose, Costa Rica in August 2015. The 44.64 time is a new NACAC Championship ...
(Date:9/4/2015)... Washington, DC (PRWEB) , ... September 04, 2015 ... ... dollar-wise they all pale in comparison to settlements under the Stark physician self-referral ... an upcoming Sept. 17 webinar from Atlantic Information Services, Inc. (AIS), will ...
(Date:9/4/2015)... ... September 04, 2015 , ... FiltersFast.com, the online retail leader ... be passed up. FiltersFast.com, will ship all orders over $50.00 for free. ... replacements. Take advantage of this promotion now through September 8, 2015. , Filtersfast.com ...
Breaking Medicine News(10 mins):Health News:USC Ophthalmology Residency Program Ranked in Top 10 by Doximity 2Health News:USC Ophthalmology Residency Program Ranked in Top 10 by Doximity 3Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 2Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 3Health News:Lalonde Gordon’s Recipe Brings Home the Gold 2Health News:Lalonde Gordon’s Recipe Brings Home the Gold 3Health News:Sept. 17 Webinar to Offer Best Practices for Physician Contracts 2Health News:FiltersFast.com Wows with a Long Labor Day Weekend Shipping Offer 2
... Duke University Medical Center say they may have figured ... health in women than in men. , Their study, ... found that poor sleep is associated with greater psychological ... risk of heart disease and type 2 diabetes. ...
... First Dual-Source CT System Brings More Innovative Diagnostics to the ... ... MALVERN, Pa., March 10 Encouraged by the outstanding,marketing success of ... Healthcare, (http://www.siemens.com/healthcare ) announces the 510(k) market clearance of four,new applications ...
... reality therapy for stroke patients. One commonly used program ... screen. For example, tennis balls are virtually thrown at ... hand motions are recorded on screen. In the first ... Dr. Larry Manevitz of the University of Haifa, together ...
... 10 MS Awareness Week March,10 - 17 unites ... of,multiple sclerosis nationwide in an effort to shine a ... MS, a disease where someone is,newly diagnosed each hour., ... you Do?, Ways To Join The MS Movement, ...
... -- Research published in the March issue of ... Psychological Science, is suggesting that we process images ... of the Negev Psychologist Tzvi Ganel and his ... an image common in psychological research that makes ...
... Oxfordshire, March 10 IBA,Health Group company iSOFT ... become its first healthcare channel partner in Europe ... provisioning solutions., The move coincides with the ... iSOFT to become the first partner to offer ...
Cached Medicine News:Health News:Poor sleep more dangerous for women 2Health News:Poor sleep more dangerous for women 3Health News:Siemens Introduces New Dual Energy Applications to SOMATOM Definition 2Health News:Siemens Introduces New Dual Energy Applications to SOMATOM Definition 3Health News:Siemens Introduces New Dual Energy Applications to SOMATOM Definition 4Health News:Virtual reality and computer technology improve stroke rehabilitation 2Health News:What Will You Do? Join the Movement to End Multiple Sclerosis During MS Awareness Week March 10-17 2Health News:What Will You Do? Join the Movement to End Multiple Sclerosis During MS Awareness Week March 10-17 3Health News:What Will You Do? Join the Movement to End Multiple Sclerosis During MS Awareness Week March 10-17 4Health News:The hand can't be fooled, study shows 2Health News:iSOFT Offers Healthcare Single Sign-On Solutions After Agreement with Sentillion 2Health News:iSOFT Offers Healthcare Single Sign-On Solutions After Agreement with Sentillion 3Health News:iSOFT Offers Healthcare Single Sign-On Solutions After Agreement with Sentillion 4
Used for implantation to reinforce soft tissue in the repair of a hernia or body wall defect. Supplied sterile in peel-open packages. Intended for one-time use....
... Laser System is a new, portable, light ... applications in dermatology, cosmetic and plastic surgery, ... laser for skin resurfacing, it is the ... lasers on the market. It provides an ...
... 800 Series KTP/YAG™ Surgical Laser System ... It is a high-power, dual-wavelength system ... surgery, orthopedics, general surgery, neurosurgery, pulmonary ... beam surgically cuts, vaporizes and coagulates ...
... laser is a versatile and durable system ... applications. With excellent hemostatic and ablative capabilities, ... optic delivery system that allows optimal energy ... and portable, the Ceralas D15/810 is a ...
Medicine Products: